November 12, 2013
First-in-Class Anabolic Catabolic Transforming Agent Shown to Reverse Cachexia's Effects in Stage III and IV Lung and Colorectal Cancer Patients PsiOxus Therapeutics, Ltd. (PsiOxus) today announced top line positive data from a Phase II clinical trial of MT-102 in cancer-related cachexia. The primary endpoint has been met in the recently completed Phase II multinational, randomized,...


Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge